null

null

null

null

null

null

null

null

null

null

null

null

null

null

Estimated net debt/EBITDA of 3-5x typical for mid-market medical imaging holdcos; a 200bps rate rise adds ~$2-4M annual interest cost assuming $100-200M debt load

Moderate-high sensitivity; floating-rate debt likely 40-60% of capital stack; 200bps increase compresses free cash flow margin by estimated 3-6 percentage points

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Taiwan/East Asia semiconductor chokepoint for imaging sensors/detectors; 2) China rare-earth supply for magnet components in MRI and CT equipment

Limited international revenue likely; primary currency risk in EUR and CAD if any cross-border deployments; sovereign devaluation exposure assessed as low-moderate

Predominantly U.S.-centric operations; secondary markets likely Canada and Western Europe; EUR/CAD devaluation risk manageable given USD-denominated contracts probable

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on OEM imaging hardware vendors (GE HealthCare, Siemens Healthineers, Philips); single-vendor input likely exceeds 30% of equipment COGS

Cloud disruption risk moderate; a 30-day termination notice would impair PACS/cloud-based image storage and AI diagnostics delivery; migration estimated 60-120 days

Secondary business model likely service/maintenance contracts and managed radiology services; less cloud-dependent but AI workflow tools create meaningful cloud reliance

High API coupling risk to PACS, EMR/EHR integrations (Epic, Cerner); deep HL7/DICOM integration creates 12-24 month switching timeline for hospital clients

Low Howey Test risk; revenue from imaging services and equipment leasing constitutes a common enterprise but lacks profit-from-others'-efforts structure; not a security

Very High

High HIPAA exposure; GDPR risk if EU patients' imaging data processed; CCPA applies if California residents served; PHI mismanagement fines could reach $1.9M per violation category

Moderate; regional imaging market consolidation via acquisitions could trigger FTC scrutiny; monopoly risk in local radiology markets if >50% share achieved post-M&A

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Estimated 55-70% recurring (service contracts, software subscriptions, managed radiology agreements); 30-45% transactional (equipment sales, per-scan billing)

Primary vectors: equipment leasing/sales, per-scan/per-read fees, SaaS-based AI diagnostics subscriptions, and managed radiology service retainers

Tiered by modality (MRI > CT > X-ray) and volume; stress test shows vulnerability to CMS reimbursement rate cuts of 5-10% which directly compress hospital client budgets

Moderate; pricing constrained by CMS fee schedules and GPO contracts; proprietary AI diagnostics layer provides limited premium pricing power of ~10-20% above commodity reads

Estimated 35-55% gross margin; hardware-heavy segments drag margins to low end; software/AI diagnostics and managed services push toward upper bound

Low free-rider risk; imaging services require active contracts; however, hospital systems may underutilize contracted scan volumes, creating effective revenue leakage of 10-20%

Revenue growth partially sublinear; radiologist headcount scales with read volume but AI-assisted reads improve throughput; doubling revenue may require only 1.4-1.6x headcount increase

Marginal cost of growth is moderate; AI diagnostic tools reduce per-read labor cost over time but equipment capital and radiologist salaries create semi-fixed cost floors

Not applicable; Lumexa operates as a corporate holdco structure, not a franchise model; compliance risk is regulatory (ACR, CMS, state health dept.) rather than franchise-driven

At 10x scale, CAC likely compresses via GPO relationships and referral networks; estimated CAC payback period of 18-36 months for hospital system clients

Weak direct network effects; AI diagnostic model improves with more imaging data (data network effect), but customer-to-customer network effects are minimal in B2B healthcare

AI displacement risk moderate-high for radiologist reads; AI can automate 20-40% of routine reads within 5 years, improving asset utilization but threatening radiologist staffing model

Tier 2 recession resistance; elective imaging (MSK, screening) declines 10-20% in downturns; emergency and oncology imaging remains stable; net revenue decline estimated 8-15%

Hospital systems and integrated delivery networks (IDNs) representing the largest revenue concentration; top 3 health system clients likely represent 30-50% of revenue

Independent radiology groups, outpatient imaging centers, and urgent care chains as secondary segment; more fragmented but higher churn risk than hospital system contracts

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital being partially reallocated toward AI/software infrastructure and cloud PACS from legacy film/hardware; however, imaging equipment refresh cycles still consume 40-60% of capex

0002071288

LMRI